期刊
IMMUNOLOGY
卷 143, 期 3, 页码 396-405出版社
WILEY
DOI: 10.1111/imm.12322
关键词
B cells; experimental autoimmune myasthenia gravis; interleukin-9; T helper cells
类别
资金
- National Nature Science Foundation for Youth of China [81000511, 81000536, 81000512]
- China Postdoctoral Science Foundation [20100480062, 2012T50356]
- Harbin Science & Technology Bureau Creative Talent Fund [2012RFQXS049]
- Science and Technology Study project of the Education Department of Heilongjiang Province [12521213]
- Open Topic of Key Laboratory of Neurobiology, General Colleges and Universities in Heilongjiang Province of China [2013HLJKLNT-10]
- Natural Science Foundation of Heilongjiang Province [LC201431]
- National Nature Science Foundation of China [81301023]
Interleukin-9 (IL-9) was initially thought to be a type 2 T helper (Th2) -associated cytokine involved in the regulation of autoimmune responses by affecting multiple cell types. However, it was recently shown that IL-9-producing CD4(+) T cells represent a discrete subset of Th cells, designated Th9 cells. Although Th9 cells have been shown to be important in many diseases, their roles in myasthenia gravis (MG) are unclear. The aim of this study was to determine whether IL-9 and Th9 cells promote the progression of experimental autoimmune myasthenia gravis (EAMG). The results showed that the percentage of Th9 cells changed during the progression of EAMG, accompanied by an up-regulation of IL-9. Blocking IL-9 activity with antibodies against IL-9 inhibited EAMG-associated pathology in rats and reduced serum anti-acetylcholine receptor IgG levels. Neutralization of IL-9 altered the Th subset distribution in EAMG, reducing the number of Th1 cells and increasing the number of regulatory T cells. Administration of an anti-IL-9 antibody may represent an effective therapeutic strategy for MG-associated pathologies or other T-cell- or B-cell-mediated autoimmune diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据